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Abstract: Background: Chronic graft-versus-host disease (cGvHD) is the leading cause of late non-
relapse mortality (transplant-related mortality) after hematopoietic stem cell transplant. Given that 
there are a wide range of treatment options for cGvHD, assessment of the associated costs and efficacy 
can help clinicians and healthcare providers allocate healthcare resources more efficiently. 
Objective: The purpose of this study was to assess the cost-effectiveness of extra-corporeal 
photopheresis (ECP) vs. rituximab (Rmb) and vs. imatinib (Imt) in patients with cGvHD at five years 
from the perspective of the Spanish National Health System. 
Patients and methods: The model assessed the incremental cost-effectiveness/utility ratio of ECP 
versus Rmb or Imt for 1,000 hypothetical patients through microsimulation cost-effectiveness 
techniques. Model probabilities were obtained from the literature. Treatment pathways and adverse 
events were evaluated taking clinical opinion and published reports into consideration. Local data on 
costs (2010 Euros) and health care resources utilization  were validated by the clinical authors. 
Probabilistic sensitivity analyses were used to assess the robustness of the model. 
Results: The greater efficacy of ECP resulted in a gain of 0.011-0.024 quality-adjusted life years (QALY) 
in the first year and 0.062-0.094 at year five compared to Rmb or Imt. The results showed that the 
higher acquisition cost of ECP vs. Imt was compensated for at 9 months by greater efficacy and vs. Rmb 
was partially compensated for (517€ year 5). After 9 months, ECP was dominant vs. Imt. The 
incremental cost-effectiveness ratio of ECP vs. Rmb was 29,646€ per LY gained and 24,442 € per QALY 
gained at year 2.5. Probabilistic sensitivity analysis confirmed the results. The main study limitation 
was that to assess relative treatment effects, only small studies were available for indirect comparison. 
Conclusion: ECP as a third-line therapy for cGvHD is a more cost-effective strategy than Rmb or Imt. 
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Editor's Notes: 
1) In the Introduction, please include some context for the fact that this study was conducted in Spain - 
e.g., prevalence of disease, utilization and expenditure rates of the treatments, reimbursement 
system, etc.? 
Authors’ comments: We have now added some comments on the Spanish context of the 
disease and the Spanish health system. However, as there are only around 200 patients 
susceptible to cGvHD in Spain annually, data are limited.   
Page:3 Line: 4-5  
Page:3 Line:12-14 
Page:5 Line:10-12 
 
2) In the Introduction, ECP was discussed as a third-line therapy but little background was provided on 
the other treatments of interests (i.e., Rmb and Imt). 
 
Author’s comments: We now include a brief explanation of the use of Rituximab and Imatinib 
Page:4 Line:20-30 
 
3) The rationale for CEA in the first paragraph of Patients and Methods seems more appropriate in the 
Introduction to discuss the rationale for this study. 
 
Authors’ comments: This section has now been moved to the Introduction as suggested. 
Page:5 Line: 4-7 
 
4) The perspective of the CEA should be presented in the Abstract. 
 
Author’s comments: We now state in the Abstract that the study was carried out from the 
perspective of the Spanish National Health System. 
Page:1 Line:14 
 
5) There are numerous grammatical errors/typos throughout the paper that should be carefully 
addressed during the revision stage perhaps by a native English writer - just three examples: 
"Incremental cost per Life year (LY) gained and incremental cost per Quality Adjusted Life year 
(QALY) gained in comparison with the other options" is a fragment and contains improper 
capitalizations. And "Both future costs and effects where discounted at 3% as indicated by the 
Spanish guidelines..." should contain "were" and not "where."  
 
Authors’ comments: The entire revised manuscript has been reviewed by a native English 
writer. As there were various errors, the changes are shown in the Track Changes version but 
are not indicated here by line and page numbers. 
 
*Detailed Response to Reviewers
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Finally, the sentence - "The model follows the patients until death or when the five year time horizon 
was reached" is missing a clause in the end stating whichever of the two events had occur first. 
 
Authors’ comments: This sentence has been changed and corrected.  
Page:6 Line:13-14 
 
6) Terming "experts" implies that a level of external validity was employed in the study design process 
and that the experts have no role in the study other than to evaluate the process/findings. While the 
authors are experts in their own rights, I believe that if the experts are themselves authors, the 
manuscript should term them as "authors" and not as "experts" to avoid unintended implications of 
impartiality. 
 
Authors’ comments: We understand the comment. To avoid doubt, we now distinguish 
between clinical authors and experts, when necessary.  
Page:1 Line:18 
Page:6 Line:25 
Page:7 Line:27-30 
Page:8 Line:2, 10-11 
 
7) It is unclear whether the experts evaluating the structured questionnaire were the same as those 
who were termed "clinical experts." If not, who were these clinical experts, their expertise/credentials, 
and whether they were authors of the paper. If yes, they should be termed "authors" and not "clinical 
experts" for the same reasons I have provided above. 
 
Authors’ comments: The opinions were those of the clinical authors or clinical experts 
according to the case, as stated in point 6.  
Page:1 Line:18 
Page:6 Line:25 
Page:7 Line:27-30 
Page:8 Line:2, 10-11 
 
8) If possible, the employment of sensitivity analysis should be noted in the Abstract to indicate that 
consistent findings were produced. 
 
Authors’ comments: We now state in the Abstract that sensitivity analysis was used and that it 
confirmed the results. 
Page:1 Line:20-21, 27-28  
 
9) This sentence is confusing to me: "These models simulate what occurs in larger populations in 
order to reach conclusions applicable to larger groups." 
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Authors’ comments: This sentence has been rewritten. 
Page:6 Line: 20-24 
 
10) "Probabilistic Sensitivity Analysis", "The Cost-effectiveness acceptability", and "Lung" are just 
three examples of inappropriate capitalization throughout the paper. A native English writer is 
recommended to help revise this paper.  
 
Authors’ comments: The entire revised manuscript has been reviewed by a native English 
writer. As there were various errors, the changes are shown in the Track Changes version but 
are not indicated here by line and page numbers. 
 
11) In the Discussion section, the first three sentences should be written more scientifically without the 
colloquial tone ("more and more limited") or unnecessary superlative ("utmost importance").  
 
Authors’ comments: These sentences have been rewritten.  
Page:12 Line:27-30 
 
Variation in care can cause differences in expenditures but the sentence is not within context. 
 
Authors’ comments: We have now provided context using the example of the situation studied. 
Page:13 Line:2-4 
 
12) The following sentence is needs to be revised more thoughtfully - "Our conclusions must be 
considered under certain perspective because ECP regimen and reimbursement system may vary 
among countries, and this is a fact that makes it necessary to adapt these results for each country." 
While the scope of inference of any CEA should be carefully considered, the authors should address 
elements of CEAs that are more influential than others that will allow for greater generalizability for 
these treatments for cGVHD from Spain to other countries. 
 
Authors’ comments: This paragraph has now been rewritten and more information provided. 
Page:13 Line:20-23 
 
13) Citation is needed for the following sentence: "A recent Spanish study, for instance, evaluated 
posaconazole vs. fluconazole cost-effectiveness in preventing invasive fungal infections in allogeneic 
hematopoietic SCT patients with GVHD."  
 
Authors’ comments: This sentence now includes a reference.  
Page:14 Line:1 
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Furthermore, a more balanced discussion is warranted in the paragraph that compares the pros and 
cons of using Markov models vs. the microsimulation technique used in this study.  
 
Authors’ comments: We now include more discussion of the pros and cons of using Markov 
models and microsimulation techniques. 
Page:14 Line:7-18 
 
And a rationale for choosing the microsimulation technique and the details/history of its application 
should be elaborated more earlier in the Methods section when the method is introduced to get the 
readers acquainted with the technique early on. 
 
Authors’ comments: We now include, in the Patients and Methods section a more detailed 
description of the microsimulation technique which we have put earlier in the section.  
Page:5 Line:17 
Page:6 Line:16-30 
Page:7 Line:1-11 
 
 
14) In the Conclusion's first paragraph, the sentence - "...our study results demonstrated that..." - 
should be specified as "...our microsimulation study results provide evidence that..."  
 
Authors’ comments: We have made the proposed change 
Page:15 Line:22-25 
 
Furthermore, the second paragraph currently is a standalone, dangling thought but needs to be 
incorporated into the first paragraph and rewritten as a concluding thought for the paper. 
 
Authors’ comments: The paragraph to which you refer has now been included in the 
Discussion and rewritten. 
Page:15 Line:7-13 
 
Reviewer #1:  
1. Please include a brief mention of limitations in the abstract. 
 
Authors’ comments: This has been done. 
Page:1 Line:28-29 
 
2. May be useful to include the distinctive clinical manifestations of cGVHD in conjunction with lines 
28-30, page 2. 
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Authors’ comments: We now describe the main clinical manifestations of cGvHD 
Page:3 Line:21-25 
 
3. Whilst, page 2. 
 
Authors’ comments: This has been corrected 
Page:3 Line:30 
 
4. Line 42, page 2: Should this be cGVHD? 
 
Authors’ comments: We now refer to cGvHD throughout the manuscript 
Page:4 Line:1 
 
5. The background describing chronic graft-vs-host disease (cGVHD) is well written. 
 
6. Line 2, page 5: pooled analysis. 
 
Authors’ comments: This has been corrected 
Page:7 Line:27 
 
7. Lower case for "cost-effectiveness", line 55, page 7. 
 
Authors’ comments: This has now been corrected. 
Page:11 Line:5 
 
8. Please be consistent with abbreviations. See "cGvHD" in line 7, page 8. 
Authors’ comments: We now refer to cGvHD throughout the manuscript 
 
9. Please revise, "talking about the published information," line 18, page 8, to less colloquial language. 
 
Authors’ comments: This has been rewritten. The manuscript has been reviewed by a native 
English writer. 
Page:11 Line:18 
 
10. Change, "3th year," line 6, page 9. 
 
Authors’ comments: This has been changed and unified.  
Page:12 Line:16-18 
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11. First para in Discussion not necessary. Would be more relevant to provide greater context to the 
use of microsimulations and how this serves to advance the economic modeling 
 
Authors’ comments: The first part of the Discussion has been modified to illustrate the context 
of the present study. More discussion is included later in the Discussion on the pros and cons of using 
microsimulation or Markow models. 
Page:5 Line:17 
Page:6 Line:16-30 
Page:7 Line:1-11 
Page:15 Line:22-25 
 
12. Please include in the discussion the deficiencies of a microsimulation when compared to a markov 
model rather than the generic limitations of a cost-effectiveness study on page 10. 
 
Authors’ comments: As stated above, we now include more discussion of the pros and cons of 
the different models. 
Page:5 Line:17 
Page:6 Line:16-30 
Page:7 Line:1-11 
Page:15 Line:22-25 
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Development of a population-based cost-effectiveness model of chronic graft versus host disease in 1 
Spain  2 
Running title: Cost-effectiveness of cChronic graft versus host disease in Spain 3 
 4 
Abstract  5 
Background: Chronic graft-versus-host disease (cGVHDcGvHD) is the leading cause of late non-relapse 6 
mortality (transplant-related mortality) after hematopoietic stem cell transplant. It deleteriously affects the 7 
quality of life in surviving patients who have otherwise have been cured of their underlying disease. 8 
Given that there are ae existence of a  wide range of treatment options for cGVHDcGvHD, assessment of 9 
the associated costs and efficacy associated can help clinicians and healthcare providers to allocate 10 
healthcare resources more efficientlyin a more efficient way. 11 
Objective: The purpose of this study was to assess the cost-effectiveness of extra-corporeal photopheresis 12 
(ECP) vsvs. rRituximab (Rmb) and vsvs., iImatinib (Imt) in patients with cGVHDcGvHD at five years 13 
from the perspective of the Spanish National Health Systemin Spain. 14 
Patients and methods: The model assessed the incremental cost-effectiveness/utility ratio of ECP versus 15 
Rmb or Imt for 1,000 hypothetical patients through microsimulation cost-effectiveness techniques. Model 16 
probabilities were obtained from the literature. Treatment pathways and adverse events were evaluated 17 
taking expertclinical opinion and published reports into consideration expert opinion (as well as 18 
publications and studies). Local data on costs (2010 Euros 2010) and health care resources utilization use 19 
were also validated by the clinical expertsauthors.  Probabilistic sensitivity analyses were used to assess 20 
the robustness of the model. 21 
Results: The greater higher efficacy of ECP resulted in a leads to a gain of 0.011–0.024 qQuality- 22 
Aadjusted lLife yYears (QALY) in the first year and 0.062-0.094 at year five compared to Rmb or Imt. 23 
The rResults showed that the higher acquisition cost of ECP vsvs. Imt was compensated for at 9 months 24 
by greater higher efficacy and vsvs. Rmb was partially compensated for (517€ year 5). After 9 months, 25 
ECP was dominant vsvs. Imt. The incremental cost-effectiveness ratio of ECP vvs.ersus Rmb was 26 
29,646€ per LY gained and 24,442 € per QALY gained at year 2.5. Probabilistic sensitivity analysis 27 
confirmed the results. The main study limitation was that to assess relative treatment effects, only small 28 
studies were available for indirect comparison. 29 
Conclusion: ECP as a third-line therapy for cGVHDcGvHD is a more cost-effective strategy than Rmb or 30 
Imt. 31 
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 1 
Introduction 2 
 3 
In Spain, between 2,000 and 2,500 hematopoietic stem cell transplants are carried out annually, a 4 
maximum rate of 54.,14 per million inhabitants, of which 34% are allogeneic)
1
. Chronic graft-versus-host 5 
disease (cGVHDcGvHD) is the leading cause of late non-relapse mortality (transplant-related mortality) 6 
after hematopoietic stem cell transplant. It deleteriously affects the quality of life in surviving patients 7 
who have otherwise have been cured of their underlying disease
1, 2, 3
. cGVHDcGvHD may have can lead 8 
to debilitating consequences resulting from profound chronic immune suppression leading to recurrent or 9 
life-threatening infections
34
. cGVHDcGvHD occurs in at least 30% to 50% of recipients of transplants 10 
from human leukocyte antigen matched siblings, and in at least 60% to 70% of recipients from unrelated 11 
donors
45
.  A Spanish study found a cumulated incidence of mild, moderate or severe  cGvHD of 29%, 12 
42% and 28%, respectively, in patients undergoing  allogeneic hematopoietic stem cell transplant using 13 
peripheral blood from related donors
6
.  14 
 15 
 16 
The diagnosis and staging working group of the National Institutes of Health Consensus Development 17 
Project on cGVHDcGvHD proposed standard criteria for the diagnosis, organ scoring and global 18 
assessment of cGVHDcGvHD severity
12, 75
. Thus, the diagnosis of cGVHDcGvHD requires the presence 19 
of at least one clinical diagnostic clinical sign of cGVHDcGvHD or the presence of aat least one 20 
distinctive clinical manifestation confirmed by biopsy or other relevant tests. cGVHD may be restricted to 21 
a single organ system, but usually several organs are usually involved.  Clinical features range from 22 
edema, erythematous rash, mucositis, diarrhea, and elevated transaminases, to more fibrotic and chronic 23 
manifestations such as sclerotic, lichen-planus skin changes, fasciitis, sicca syndrome, joint contractures, 24 
esophageal strictures, and bronchiolitis obliterans
7
. TFurthermore, the proposed global assessment of 25 
severity (mild, moderate, or severe) is derived by combining organ and site-specific scores
12, 57
. 26 
 27 
 28 
Prednisone, together with a calcineurin inhibitor (CI), is considered the standard regimen for the primary 29 
treatment of cGVHDcGvHD
68
. Whilst While half of the patients respond to first-line treatment, the 30 
prognosis of steroid- refractory cGVHDcGvHD remains poor
79
. There is no standard approach to treat 31 
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refractory GVHDcGvHD, although there is a long list of immunosuppressive drugs and other agents for 1 
salvage therapy. IThus, different immunosuppressive treatments that inhibit T cell activation, 2 
proliferation or survival includeare available such as mycophenolate mofetil, daclizumab, sirolimus 3 
(rapamycin), extra-corporeal photopheresis (ECP) and pentostatin (deoxycoformycin)
 810
. In addition, new 4 
strategies such as etanercept, rituximab (Rmb) and or imatinib (Imt) have also been evaluated
68, 108
. 5 
However, responses to immunosuppressive drugs are often partial, and patients continue to experience 6 
disease symptoms of the disease that can significantly impair the quality of life. 7 
 8 
ECP is a therapeutic approach based on the biological effect of liquid 8-methoxypsoralen (8-MOP) and 9 
ultraviolet light A on mononuclear cells collected by apheresis, and reinfused into the patient
810
. This 10 
therapy allows patient treatment using a closed system specifically designed to treat these cells. Therakos 11 
photopheresis instruments are the only integrated system available for photopheresis with an 12 
independently- validated operating standard and CE Mark granted. The liquid 8-MOP eliminates the side 13 
effects of oral 8-MOP (such as the gastrointestinal side effects of psoralen and blood concentration 14 
variability in its pharmacokinetics), and the need for premedication with this drug and further monitoring 15 
of blood levels
911
. ECP, originally developed for the treatment of skin manifestations of cutaneous T-cell 16 
lymphoma
120
,. has proven effective across a variety of indications, especially most widely acute and 17 
chronic graft-versus-host diseaseGvHD, in both adult and pediatric patients, resistant to standard 18 
protocols
131
.  19 
Although T lymphocytes are the therapeutic target of options for the treatment of cGvHD, there is 20 
growing evidence of the importance of B lymphocytes in the development of the disease. These findings 21 
have led to evaluation of the role of rituximab, a chimeric (mouse/human) monoclonal antibody against 22 
the protein CD20, in the treatment of cGvHD
8
. 23 
 24 
Imatinib is a potent inhibitor of the tyrosine kinases ABL, platelet-derived growth factor receptor alphfa 25 
and beta, c-KIT, ARG, and LCK. It has proven clinical efficacy in the treatment of the following 26 
malignant neoplasms, which are characterized by constitutive activation of these tyrosine kinases: chronic 27 
myeloid leukemia, Philadelphia chromosome-–positive acute lymphocytic leukemia, 28 
dermatofibrosarcoma protuberans, myeloproliferative disorders due to chromosomal rearrangements in 29 
the PDGF-R locus, and gastrointestinal stromal tumors with mutations in c-KIT
8
.  30 
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 1 
Given that there is e existence of a wide range of treatment options for cGVHDcGvHD, assessment of the 2 
associated costs and efficacy associated can help clinicians and healthcare providers to allocate healthcare 3 
resources more efficientlyin a more efficient way. Cost-effectiveness analysis (CEA) is a tool decision-4 
makers can use to assess and potentially improve the performance of their health systems
124, 135
. It 5 
indicates which interventions provide the best highest "value for money" and enables helps them choose 6 
thethe  interventions which maximize health for the available resources to be chosen. Therefore, the 7 
purpose of this study was to develop a cost-effectiveness population-based simulation analysis of 8 
cGVHDcGvHD in Spain that may can be used to quantify the future health and economic benefits of ECP 9 
versus Rmb or Imt in addition to the usual care of cGVHDcGvHD after prior treatment failure. Spain is a 10 
country with 47 million inhabitants with access to universal public health care free at the point of 11 
delivery.  12 
 13 
 14 
Patients and methods 15 
 16 
We used a The microsimulation model to  assessed the incremental cost-effectiveness ratio (ICER) and 17 
the incremental cost-utility ratio (ICUR) of ECP versus Rmb or Imt for 1,000 hypothetical patients 18 
(fFigure 1). Cost-effectiveness analysis (CEA) is a tool decision-makers can use to assess and potentially 19 
improve the performance of their health systems
12, 13
. It indicates which interventions provide the highest 20 
"value for money" and helps them choose the interventions which maximize health for the available 21 
resources. Mean cumulative costs and cumulative scores of effectiveness at the end of the 5-year cycle 22 
were then obtained to facilitate ICER and ICUR in terms of incremental cost per improvement gained 23 
measured as the i. Incremental cost per lLife year (LY) gained and incremental cost per qQuality 24 
aAdjusted lLife year (QALY) gained in comparison with the other options.  25 
 26 
The ICER of ECP versus the alternatives was , compared using by means of the  following formula: 27 
eAlternativECP
eAlternativECP
essEffectivenessEffectiven
CostsCosts


 28 
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We have also calculated the incremental cost-utility ratio (IICUR) by using effectiveness units expressed 1 
in QALYs (cost–utility analysis). This is widely recognized as a useful approach for measuring and 2 
comparing the efficiency of different health interventions. QALYs are overall measures of health 3 
outcome that weight the life expectancy of a patient with an estimate of their health-related quality -of- 4 
life score (on a scale of 0 to 1, where 0 is equivalent to death, and 1 is equivalent to full health). 5 
 6 
 7 
The study was designed from the perspective of the Spanish National Health System (NHS) and health-8 
care decision-makers, including only direct health-care costs. FBoth future costs and effects where 9 
discounted at 3% as indicated by the Spanish guidelines
13
 guidelines
15
 and all costs were we inflinflated 10 
all costs to 2010 Euros€ using the consumer price index for all goods and services164. The cycle length of 11 
the model was three3 months, as most of the data sources, for the sake of efficacy, are calculated using on 12 
this frequency. The model followeds the patients until death or the when the five year time horizon was 13 
reached, whichever occurred first.  14 
 15 
Microsimulation  16 
 17 
Microsimulation is a discrete simulation technique that facilitates modeling of the behavior of single 18 
individuals in a complex system, i.e. multiple organ dysfunction syndrome
17-19
. Microsimulation models 19 
are mathematical computer-based models that operate from the level of the individual upwards. They 20 
simulate the behaviour of the population, taking into account the heterogeneous composition of the target 21 
population without focusing on a representative or average individual. This implies that the population is 22 
stratified across health states and attributes (e.g. age, disease severity, risk exposure) identified as relevant 23 
to the problem analysed.  A hypothetical stable sample of patients with clinical characteristics based on 24 
published reports and adjusted by clinical opinion is used to generate representative patients randomly
19
.  25 
 26 
 27 
In our cost-effectiveness microsimulation analysis, up to 1,000 hypothetical patients were randomly 28 
generated, one by one, taking into account the probability that every organ in the body was affected and 29 
the degree of severity (Table 1). Patients were entered in the model one at a time with the same or 30 
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different characteristics. Each organ involvement was scored from 0 to 3 (from none to severe organ 1 
involvement) and  cGvHD was classified as (i) mild cGvHD: one or two organs involved (except lungs) 2 
with no clinically-significant impairment, i.e. maximum score 1 in all affected organs; (ii) moderate 3 
cGvHD: three or more organs involved without functional impairment (maximum score 1) or at least one 4 
organ with clinically significant involvement but no major disability (maximum score 2) or lung 5 
involvement with score 1; and (iii) severe cGvHD: major disability in any organ (score of 3) or lung score 6 
2
2
. The efficacy of each treatment and organ evaluated and survival for each disease state was applied 7 
(Table 2). Transition probabilities were dependent on the individual characteristics (organ, degree of 8 
severity per organ and previous NIH global score). Patient characteristics were considered independently 9 
(eg. selection of the affected organ and degree of severity), as this potential relationship is not available in 10 
the literature. Patients generated in the same way were evaluated for each alternative treatment. 11 
 12 
Parameters of the model  13 
 14 
Model probabilities concerning the efficacy of ECP, Rmb and Imt and the degree of severity per organ 15 
affected were obtained from published reports literature and internet searches of relevant medical 16 
databases (e.g. PUBMED, CINAHL, DARE, NHS EED, HTA) as well as a targeted search of relevant 17 
bBone mMarrow tTransplantation- related journals 
6,1205-4852
. (Table 1 and 2). Key words searched for 18 
included extracorporeal photopheresis, ECP, treatment cGVHDcGvHD treatment, cGVHDcGvHD, 19 
rRituximab and iImatinib. The systematic review was limited to evaluations involving adults published in 20 
and whose publication language was Spanish or English. Studies of about treatment efficacy per affected 21 
organ for any time horizon were included (clinical trial, observational studies, cohort studies, cases 22 
studies). The summary measure from a meta-analysis was used to derive the probability of treatment 23 
success in our cost-effectiveness analysis. To In order to detect which organs would be globally affected 24 
in our hypothetical patients, we searched for information on the looked for the organs affected in the 25 
studies reviewed and made a pooled analysis. information, which were published in the reviewed studies, 26 
and we did a pooled analysis with them. Based on the clinical expert opinion and experience of of two 27 
authors (JP and JS)clinical authors, the probabilities of continuing with the treatment were dependent on 28 
the health status reached in each cycle (complete response 100%, partial response 65%, stable disease 29 
33% and progression 0%). Expert Clinical opinion was compiled using a structured questionnaire in two 30 
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interviews, the first . The first one had an exploratory and the second for objective and the second had a 1 
goal based on validation and consensus. Clinical authorsExpert were selected according to clinical 2 
experience and national and international research achievementsselection was carried out according to 3 
their practice experience and their national and international achievements in research. Experts were 4 
included in the manuscript authorship.  Table 3 shows the utilities associated with to different disease 5 
states, the disutility associated with to neutropenia and survival rates. Neutropenia is an adverse event 6 
associated with drug treatments included in our study 
4953, 540
. 7 
 8 
 9 
TOn the other hand, treatment pathways and adverse events were derived from the clinical expert opinion 10 
of two authors (JP and JS). clinical authors. Local data on healthcare resource use and costs were used 11 
and validated by the same authorsclinical authors, experts in that 
51
field
55,562
 Table 4 shows the cost 12 
derived from by the pre-administration of treatments, pharmacological costs based on the type of 13 
response, the cost associated with to different disease states and adverse events. To determine the cost of 14 
the whole ECP treatment, the following se factors were taken into account: the Therakos’ European list 15 
price for the ECP Kit (990€), as well as the need for of 20 minutes of light assembly, 5 ml of 16 
mMethoxsalen (Uvadex
1
), 10,000 IUI of enoxaparin, 0.5 L of physiological saline, a hematology 17 
consultation visit and 2 hours of nursing time. The initial guideline for ECP sessions, recommended by 18 
study our clinicians participating in the study, was 3 sessions per week during the first 2 weeks and a 19 
single session every 15 days until patient the evaluation of the evaluation at patient after 3 months. 20 
 21 
In contrast to other treatments, including various monoclonal antibodies,  independent reports including 22 
Wolff et al.
8
, Flowers et al.
37
, Jagasia et al.
38 
and Miller et al.
29  
have shown that ECP does not result in 23 
lead to an increased risk of infection. This has been shown in several independent publications such as 24 
Wolff et al.
68
. Flowers et al.
337
, Jagasia et al.
384 
or Miller et al.
295
. TThe incidence of complications or 25 
reported side-effects is approximately < 0.003% after more than 500,000 ECP treatments worldwide since 26 
1987 in patients with cutaneous T-cell lymphoma and graft-versus-host disease GVHD patients 
217
. All 27 
studies essentially reported essentially only mild side-effects, including  of the treatment. These were 28 
nausea, high temperature and headache, without any associated cost. Our study made a conservative 29 
                                                 
1
 Uvadex is a registered trade name of Johnson And Johnson Medical Limited, New Brunswick, US. 
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assumption which In our study we have excluded the cost of infection, even though  cost although a major 1 
disadvantage of Rmb and Imt is the strong immunosuppressive effect, which may lead to life-threatening 2 
fungal infections, bacterial sepsis and viral reactivations
79
. This was a conservative assumption in our 3 
study. Another factor assumption that was not taken into consideration was the steroid sparing effect 4 
reported after ECP treatment: , for example Couriel D et al. reported a 22% cumulative discontinuation of 5 
steroids at one year after ECP initiation and a 10% discontinuation rate of all immunosuppressive therapy 6 
at one year after ECP initiationat one year after ECP initiation 
573
. 7 
 8 
 9 
Microsimulation  10 
 11 
Microsimulation is a discrete simulation technique that facilitates modeling of which allows us to model 12 
the behavior of single individuals in a complex system, i.e. multiple organ dysfunction 13 
syndromemultiorganic failure
5174-5619
. Microsimulation models are mathematical computer- based models 14 
that operate from the level of the individual upwards. They simulate the behaviour of the population, 15 
taking into account the heterogeneous composition of the target population without focusing on a 16 
representative or average individual.These models simulate what occurs in larger populations in order to 17 
reach conclusions applicable to larger groups. This implies that the population is stratified across health 18 
states and attributes (e.g. age, disease severity, risk exposure) identified as being relevant to the problem 19 
analysedfor the decision problem.  A Starting with a hypothetical stable sample of patients with clinical 20 
characteristics based on published reportsthe literature and adjusted by clinicalexpert opinion is used to 21 
generate representative patients’ randomly5619.  22 
 23 
 24 
In our cost-effectiveness microsimulation analysis, up to 1,000 hypothetical patients were randomly 25 
generated, one by one, taking into account the probability that every organ in the body was affected and 26 
the degree of its severity (Table 1). Patients wereare entered in the model one at a time with the same or 27 
different characteristics. Each organ involvement was scored from 0 to 3 (from none to severe organ 28 
involvement) and so that cGVHDcGvHD was classified asinto (i) mild cGVHDcGvHD: one or two 29 
organs involved (except lungs) with no clinically- significant impairment, i.e. maximum score 1 in all 30 
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affected organs; (ii) moderate cGVHDcGvHD: three or more organs involved without functional 1 
impairment (maximum score 1) or at least one organ with clinically significant involvement but no major 2 
disability (maximum score 2) or lung involvement with score 1; and (iii) severe cGVHDcGvHD: 3 
indicates major disability in any organ (score of 3) or lung score 2
12
. TFurthermore, the efficacy of each 4 
treatment and organ evaluated and survival for each disease state was applied (Table 2). Transition 5 
probabilities were dependent on the individual’s characteristics (organ, degree of severity per organ and 6 
previous NIH global score previous). Patients characteristics were considered independently (eg. selection 7 
of the affected organ and degree of severity degree), as because this potential relationship is not available 8 
in the literature. Patients generated in the same way were evaluated for each alternative treatment. 9 
 10 
 11 
Probabilistic Sensitivity sensitivity Analysis analysis  12 
 13 
To evaluate the influence of uncertainty due to patients characteristics, parameter values and modeling 14 
assumptions on the results of the model results, and to confirm the robustness of the outcomes obtained, a 15 
probabilistic sensitivity analysis was performed by simulating 1,000 times (each parameter being 16 
randomly selected from the distribution) and with 1,000 trials per analysis 
578
. For the sensitivity analysis, 17 
fixed probability distributions were selected for each variable (log-normal distribution for to costs, 18 
resources used and utilities, a normal distribution for was used to patient’s weight and height and a 19 
Ddirichlet distribution for to the probabilities) and the parameters of each distribution were estimated 20 
according to the primary data collected
598
.  21 
 22 
 23 
Based on pProbabilistic sSensitivity aAnalysis, the incremental cost and incremental effect of ECP vsvs.. 24 
comparators was represented visually using the incremental cost-effectiveness plane
5609
. The horizontal 25 
axis divides the plane according to incremental cost (positive above, negative below) and the vertical axis 26 
divides the plane according to incremental effect (positive to the right, negative to the left). This divides 27 
the incremental cost-effectiveness plane into four quadrants through the origin. We included the 28 
unofficial, but broadly accepted, Spanish threshold line (30,000€/QALYs) in the plane, in order to decide 29 
whether if ECP offered "good" value for money
610
. This threshold represents the maximum amount that 30 
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the decision- maker is willing to pay for health effects (maximum acceptable ceiling ratio). The 1 
intervention is deemed cost-effective if the ICER falls below this threshold and deemed not cost-effective 2 
otherwise.  3 
An acceptability curve was then constructed from the incremental cost and QALYs between different 4 
strategies for the 1,000 simulations. The Costcost-effectiveness acceptability curve showed the 5 
probability that ECP was cost-effective against compared to comparators over a range of values for the 6 
maximum acceptable ceiling ratio. 7 
 8 
 9 
Results 10 
 11 
The main organs affected in for patients with cGvHD were the skin (88%), mucosamucous membranel 12 
(43%), lLiver (37%), lungs (22%) and gGastro intestinal tract (14%). Severity was mainly mild In all 13 
cases the most observed severity was mild severity (range 60.7% - 93.5%) in all cases except in the lung 14 
where severity was moderate in 60% of casesseverity was the most observed (60%). 15 
 16 
 17 
With respect to the Talking about the published information we obtained on the for the three 18 
comparedtreatments comparedtreatments, , the number of patients included in studies reporting data on 19 
ECP data was higher than in those the ones related to Rmb or Imt. Data related to complete response and 20 
improvement rates (complete or partial response) were higher with ECP for all the affected organs except 21 
for skin, where improvement was similar to Rmb. The On the other hand, the progression rate was higher 22 
with Imt for the skin and mucosamucous membranel, higher with with Rmb for the liver the progression 23 
rate was higher for liver and higher with ECP for the lungs and gastrointestinal tract. the progression rate 24 
was higher for Lung lung and GI. However, the number of patients studied with Lung lung and 25 
gastrointestinal involvement was lower for GI for Rmb and Imt than for were smaller in comparison with 26 
ECP studies. 27 
 28 
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The higher purchasing cost of ECP vsvs.. Imt was compensated for at 9 months due to its greater months 1 
for its higher efficacy. Our results show the In our results, the global treatment cost of ECP wasis € 518-2 
4,000 higher than Rmb. The difference in disease improvement (% of complete or partial response) shows 3 
that ECP produceds an improvement gain of 6.2% after the first year vvs. ersus Rmb and 6.7% 4 
vs.compared to Imt (Table 5). The results show that the greater higher efficacy of ECP leads to a gain of 5 
0.011 Quality quality Adjusted adjusted Life life Year year (QALY) vvs. ersus Rmb and 0.024 QALY 6 
vsersus. Imt at one first year and a gain of 0.062 QALY vvs.ersus Rmb and 0.094 QALY vvs.ersus Imt at 7 
year five (Table 5). After 9 months, ECP was dominant (cheaper and more effective) vvs.ersus Imt for all 8 
regarding all the parameters: the cost per improvement gained, the cost per life year (LY) gained and the 9 
cost per QALY gained (Table 5). After On the other hand, after 2.5 years ECP was cost-effective vsvs.. 10 
Rmb with an ICER below € 30,000 (29,646€ per LY gained and 24,442 € per QALY gained). 11 
 12 
The results of the probabilistic analysis (1,000,000 different simulated patients) showed that, taking into 13 
account the uncertainty in the variables of the model, starting the treatment of cGvHD with ECP 14 
remaineds dominant and more cost-effective versus the other alternatives (30.7% dominant vsvs.. Rmb 15 
and 83.0% dominant vsvs.. Imt at year 33
th
 year and 32.1% dominant vsvs.. Rmb and 78.2% dominant 16 
vsvs.. Imt at year 55
th
 year) (Figures 2 and 3). Assuming a willingness-to-pay threshold of €30.000 per 17 
QALY gained, there was a 56.5% chance at year 3 and a 3th year and 70.1% chance at year 55
th
 year that 18 
ECP was a cost-effective intervention vsvs.. Rmb and Imt. On the other hand, Imt was the leastss cost-19 
effective treatment vs others. This indicates that, even when the being a decision- maker’s willingness to 20 
pay for the increment in quality-adjusted life months is almost 30,000 €, the treatment of choice should 21 
still be ECP. 22 
 23 
 24 
Discussion 25 
 26 
Economic evaluations are acquiring greater importance due to limitations on because economic resources, 27 
the expense of many new treatments and the need to allocate health spending as effectively as possible 28 
and to inform decision making are getting more and more limited. Some new treatments are expensive 29 
and economic evaluations are of utmost importance to allocate the best healthcare resources and help 30 
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healthcare providers to decision making. Furthermore, variations in clinical practice can cause substantial 1 
differences in expenditures. For example, the number of sessions of ECP is not standardized yet in all 2 
countries. Likewise the escalation of therapy is not yet clear, which is important given that this is a 3 
salvage therapy.  Traditionally, healthcare companies were required to provide evidence to demonstrate 4 
their product′s safety, efficacy and quality for the purposes of registration and reimbursement 124, 135. 5 
Increasingly, a value for money demonstration,  has been added which requires companies to make 6 
develop economic evaluations studies to support the reimbursement process, has been added, increasing 7 
the importance of . Therefore, hHealth eEconomics eEvaluations have become very relevant nowadays. 8 
New national and international guidelines are being published and updated continuously, representing an i 9 
what means an increase in of healthcare sources to aid decision making in the processes decision and in 10 
the number of countries with value for money demonstrations
153, 61
.  11 
 12 
 13 
There are no reported For the time being there is not any published economic evaluations including ECP, 14 
Rmb or Imt as third-line treatment of in the treatment of cGVHDcGvHD. However, a recent consensus 15 
conference on clinical practice in cGvHD involving German-speaking countries Therefore, the present 16 
study is the first economic evaluation analysis comparing these 3 therapies of reference as third-line 17 
treatment in cGVHDcGvHD. Although we studied ECP in third-line treatment, a recent German speaking 18 
Countries consensus conference on clinical practice in cGvHD chronic GVHD included ECP as a second-19 
line treatment due to its safety profile and well documented activity 
68
. Evaluation of our conclusions 20 
should consider not only that the Spanish health system is universal and public, but also that the elements 21 
that most influenced the results of the CEA were the number of sessions of ECP, the dosing guidelines of 22 
rituximab and imatinib and the cost of day hospital. Our conclusions must be considered with some 23 
perspective, because the under certain perspective because ECP regimen and reimbursement system may 24 
vary between among countries, making it necessary to adapt our results to each countryand this is a fact 25 
that makes it necessary to adapt these results for each country. 26 
 27 
There are some Some economic evaluations of related to cGVHDGvHD treatment already exist. A recent 28 
Spanish study, for instance, evaluated the cost-effectiveness of posaconazole vsvs.. fluconazole cost-29 
effectiveness in preventing invasive fungal infections in allogeneic hematopoietic stem cell 30 
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transplantation SCT patients with graft-versus-host disease GVHD
62
. , using a However, in contrast to our 1 
study, they performed a Markov model. Our study used In the present study we developed a 2 
microsimulation technique because it alloweds us to start from the clinical behaviour of the patientclinical 3 
patient level behavior  and can it is possible incorporate different responses at different organ levels. 4 
Therefore, the model differs from is is what makes these models different from aggregate models 5 
(Markov models), in which the explanatory variables represent group properties
54
properties
17-5619
. 6 
Although Markov models are widely used in economic evaluation, as they facilitate the representation of 7 
recurrent events, they assume that patients who reach a health status are homogenous.   This is usually 8 
overcome by creating more health states in order to ensure that this is so. In our specific case, the 9 
proliferation of health states, and of possible responses (complete response, partial response, stable 10 
disease and progression) for each organ (skin, liver, lungs,..) does not solve the problem because, in order 11 
to evaluate the result of treatment, a combined score which indicates disease severity (mild, moderate, 12 
severe) must be calculated. This require around 1024 (4
5
) different health states grouped according to 13 
severity, meaning that the use of a Markov model would be unviable. In contrast, microsimulation, which 14 
evaluates the individual dynamically, is capable of following the complete natural history of that 15 
individual. However, on drawback of microsimulation is that it requires the generation of a large number 16 
of individuals in order to adjust to the pre-established parameters and minimize the error of the 17 
simulation. This requires many hours, or even days, of computing time.   18 
 19 
 20 
Our study The present cost-effectiveness study has some everal limitations. Firstly, we used a theoretical 21 
mathematical model which has made different assumptions and has used data from different sources. 22 
However, economic evaluation models are tools that help decision making, and make it easier to the 23 
representation of real world complexity in a simplified and understandable way. Thus, models help to 24 
simulate alternative scenarios if there is no evidence available to estimate some probabilities or medical 25 
literature there is a lack of published studies investigating long term outcomes of patients receiving these 26 
treatments or costs. In fact, microsimulation models have present some major advantages over cohort-27 
based models, increasing the reliability of the results and being largely compatible with the existing state 28 
of the art, evidence-based literature. Secondly, the protocols of treatment and the time horizon of studies 29 
were quite variable, ranging from a cycle of treatment every 1 and 4 weeks and a time horizon of 3 and 6 30 
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months, but in most cases the treatment is tailored to the patient clinical response. Thirdly, in oour 1 
analysis we excluded the incorporation of the reduction in of immunosuppressive ant therapies 2 
attributable toby ECP, even though some . Although some studies have provided evidence of such as 3 
suggested areduction n immunosuppressant therapdue to the fact that ies reduction related to ECP 4 
treatment is associated with to lower morbidity and mortality
631, 642
. 5 
 6 
COn the other hand, Overall, cost-effectiveness evaluations of healthcare interventions depend on strong 7 
clinical evidence in order to establish benefits and risks. Data validity is crucial for the overall validity of 8 
the model predictions.  Estimates derived from large-scale, multicenter, randomized clinical trials are 9 
widely considered as the ‘gold standard’ for assessing efficacy, but these data are not available in our 10 
case. Therefore, our results should be taken with caution, as they depend on data from small studies or 11 
case studies, which are inherently more uncertain and have a lower level of evidence. However, no other 12 
data is available.   13 
  14 
 15 
Conclusion 16 
The efficacy and safety profile of ECP has been widely proven. has widely demonstrated its good efficacy 17 
and safety profile. Thus, aAlthough only 5-–10% of circulating mononuclear cells areis treated during one 18 
ECP procedure, the treatment has long-lasting immunomodulatory effects
653
. The main advantage of ECP 19 
treatment is the lower frequency of treatment-related side effects related to treatment, and the only 20 
disadvantages are the practical efforts required (availability of trained staff availability) and higher 21 
acquisition treatment costs to implement the ed therapy in a specific center
635
. However, our 22 
microsimulation study results results provide evidence demonstrated that ECP is cheaper and more 23 
effective than compared to imatinib Imt and more cost-effective than compared to rituximabRmb, when 24 
using currently- accepted Spanish willingness- to- pay thresholds in Spain. 25 
 26 
Overall, cost-effectiveness evaluations of healthcare interventions depend on strong clinical evidence in 27 
order to establish benefits and risks. Data validity is crucial for the overall validity of the model 28 
predictions. Estimates derived from large-scale, multicenter, randomized clinical trials are widely 29 
considered as the ‘gold standard’ for assessing efficacy, but these data are not available in our case. 30 
31 
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Development of a population-based cost-effectiveness model of chronic graft versus host disease in 1 
Spain  2 
Running title: Cost-effectiveness of chronic graft versus host disease in Spain 3 
 4 
Abstract  5 
Background: Chronic graft-versus-host disease (cGvHD) is the leading cause of late non-relapse mortality 6 
(transplant-related mortality) after hematopoietic stem cell transplant. Given that there are a wide range of 7 
treatment options for cGvHD, assessment of the associated costs and efficacy can help clinicians and 8 
healthcare providers allocate healthcare resources more efficiently. 9 
Objective: The purpose of this study was to assess the cost-effectiveness of extra-corporeal photopheresis 10 
(ECP) vs. rituximab (Rmb) and vs. imatinib (Imt) in patients with cGvHD at five years from the 11 
perspective of the Spanish National Health System. 12 
Patients and methods: The model assessed the incremental cost-effectiveness/utility ratio of ECP versus 13 
Rmb or Imt for 1,000 hypothetical patients through microsimulation cost-effectiveness techniques. Model 14 
probabilities were obtained from the literature. Treatment pathways and adverse events were evaluated 15 
taking clinical opinion and published reports into consideration. Local data on costs (2010 Euros) and 16 
health care resources utilization  were validated by the clinical authors. Probabilistic sensitivity analyses 17 
were used to assess the robustness of the model. 18 
Results: The greater efficacy of ECP resulted in a gain of 0.011–0.024 quality-adjusted life years (QALY) 19 
in the first year and 0.062-0.094 at year five compared to Rmb or Imt. The results showed that the higher 20 
acquisition cost of ECP vs. Imt was compensated for at 9 months by greater efficacy and vs. Rmb was 21 
partially compensated for (517€ year 5). After 9 months, ECP was dominant vs. Imt. The incremental 22 
cost-effectiveness ratio of ECP vs. Rmb was 29,646€ per LY gained and 24,442 € per QALY gained at 23 
year 2.5. Probabilistic sensitivity analysis confirmed the results. The main study limitation was that to 24 
assess relative treatment effects, only small studies were available for indirect comparison. 25 
Conclusion: ECP as a third-line therapy for cGvHD is a more cost-effective strategy than Rmb or Imt. 26 
 27 
Key words: Cost-effectiveness, chronic graft, host disease, extra-corporeal photopheresis. 28 
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Introduction 1 
 2 
In Spain, between 2,000 and 2,500 hematopoietic stem cell transplants are carried out annually, a 3 
maximum rate of 54.14 per million inhabitants, of which 34% are allogeneic
1
. Chronic graft-versus-host 4 
disease (cGvHD) is the leading cause of late non-relapse mortality (transplant-related mortality) after 5 
hematopoietic stem cell transplant. It deleteriously affects the quality of life in surviving patients who 6 
have otherwise been cured of their underlying disease
 2, 3
. cGvHD may have debilitating consequences 7 
resulting from profound chronic immune suppression leading to recurrent or life-threatening infections
4
. 8 
cGvHD occurs in at least 30% to 50% of recipients of transplants from human leukocyte antigen matched 9 
siblings, and in at least 60% to 70% of recipients from unrelated donors
5
.  A Spanish study found a 10 
cumulated incidence of mild, moderate or severe  cGvHD of 29%, 42% and 28%, respectively, in patients 11 
undergoing  allogeneic hematopoietic stem cell transplant using peripheral blood from related donors
6
.  12 
 13 
The diagnosis and staging working group of the National Institutes of Health Consensus Development 14 
Project on cGvHD proposed standard criteria for the diagnosis, organ scoring and global assessment of 15 
cGvHD severity
2, 7
. The diagnosis of cGvHD requires the presence of at least one clinical diagnostic sign 16 
of cGvHD or at least one distinctive clinical manifestation confirmed by biopsy or other relevant tests. 17 
cGVHD may be restricted to a single organ system, but several organs are usually involved. Clinical 18 
features range from edema, erythematous rash, mucositis, diarrhea, and elevated transaminases, to more 19 
fibrotic and chronic manifestations such as sclerotic, lichen-planus skin changes, fasciitis, sicca 20 
syndrome, joint contractures, esophageal strictures, and bronchiolitis obliterans
7
. The proposed global 21 
assessment of severity (mild, moderate, or severe) is derived by combining organ and site-specific 22 
scores
2, 7
. 23 
 24 
Prednisone, together with a calcineurin inhibitor, is considered the standard regimen for the primary 25 
treatment of cGvHD
8
. While half of the patients respond to first-line treatment, the prognosis of steroid-26 
refractory cGvHD remains poor
9
. There is no standard approach to treat refractory cGvHD, although 27 
there is a long list of immunosuppressive drugs and other agents for salvage therapy. Immunosuppressive 28 
treatments that inhibit T cell activation, proliferation or survival include mycophenolate mofetil, 29 
daclizumab, sirolimus (rapamycin), extra-corporeal photopheresis (ECP) and pentostatin 30 
(deoxycoformycin)
 10
. In addition, new strategies such as etanercept, rituximab (Rmb) and imatinib (Imt) 31 
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have also been evaluated
8, 10
. However, responses to immunosuppressive drugs are often partial, and 1 
patients continue to experience disease symptoms that can significantly impair the quality of life. 2 
 3 
ECP is a therapeutic approach based on the biological effect of liquid 8-methoxypsoralen (8-MOP) and 4 
ultraviolet light A on mononuclear cells collected by apheresis, and reinfused into the patient
10
. This 5 
therapy allows treatment using a closed system specifically designed to treat these cells. Therakos 6 
photopheresis instruments are the only integrated system available for photopheresis with an 7 
independently-validated operating standard and CE Mark granted. The liquid 8-MOP eliminates the side 8 
effects of oral 8-MOP (such as the gastrointestinal side effects of psoralen and blood concentration 9 
variability in its pharmacokinetics), and the need for premedication with this drug and further monitoring 10 
of blood levels
11
. ECP, originally developed for the treatment of skin manifestations of cutaneous T-cell 11 
lymphoma
12
, has proven effective across a variety of indications, especially acute and chronic graft-12 
versus-host disease in both adult and pediatric patients resistant to standard protocols
13
.  13 
 14 
Although T lymphocytes are the therapeutic target of options for the treatment of cGvHD, there is 15 
growing evidence of the importance of B lymphocytes in the development of the disease. These findings 16 
have led to evaluation of the role of rituximab, a chimeric (mouse/human) monoclonal antibody against 17 
the protein CD20, in the treatment of cGvHD
8
. 18 
 19 
Imatinib is a potent inhibitor of the tyrosine kinases ABL, platelet-derived growth factor receptor alpha 20 
and beta, c-KIT, ARG, and LCK. It has proven clinical efficacy in the treatment of the following 21 
malignant neoplasms, which are characterized by constitutive activation of these tyrosine kinases: chronic 22 
myeloid leukemia, Philadelphia chromosome-positive acute lymphocytic leukemia, dermatofibrosarcoma 23 
protuberans, myeloproliferative disorders due to chromosomal rearrangements in the PDGF-R locus, and 24 
gastrointestinal stromal tumors with mutations in c-KIT
8
.  25 
 26 
Given that there is a wide range of treatment options for cGvHD, assessment of the associated costs and 27 
efficacy can help clinicians and healthcare providers allocate healthcare resources more efficiently. Cost-28 
effectiveness analysis (CEA) is a tool decision-makers can use to assess and potentially improve the 29 
performance of health systems
14, 15
. It indicates which interventions provide the best value for money and 30 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
4 
 
enables the interventions which maximize health for the available resources to be chosen. The purpose of 1 
this study was to develop a cost-effectiveness population-based simulation analysis of cGvHD in Spain 2 
that may be used to quantify the future health and economic benefits of ECP versus Rmb or Imt in 3 
addition to the usual care of cGvHD after prior treatment failure. Spain is a country with 47 million 4 
inhabitants with access to universal public health care free at the point of delivery.  5 
 6 
Patients and methods 7 
 8 
We used a microsimulation model to assess the incremental cost-effectiveness ratio (ICER) and the 9 
incremental cost-utility ratio (ICUR) of ECP versus Rmb or Imt for 1,000 hypothetical patients (Figure 10 
1). Mean cumulative costs and cumulative scores of effectiveness at the end of the 5-year cycle were 11 
obtained to facilitate ICER and ICUR in terms of incremental cost per improvement gained measured as 12 
the incremental cost per life year (LY) gained and incremental cost per quality adjusted life year (QALY) 13 
gained in comparison with the other options.  14 
 15 
The ICER of ECP versus the alternatives was compared using the formula: 16 
eAlternativECP
eAlternativECP
essEffectivenessEffectiven
CostsCosts


 17 
We calculated the ICUR by using effectiveness units expressed in QALYs (cost–utility analysis). This is 18 
widely recognized as a useful approach for measuring and comparing the efficiency of different health 19 
interventions. QALYs are overall measures of health outcome that weight the life expectancy of a patient 20 
with an estimate of their health-related quality of life score (on a scale of 0 to 1, where 0 is equivalent to 21 
death, and 1 is equivalent to full health). 22 
 23 
The study was designed from the perspective of the Spanish National Health System and health-care 24 
decision-makers, including only direct health-care costs. Future costs and effects were discounted at 3% 25 
as indicated by Spanish guidelines
15
 and all costs were inflated to 2010 Euros using the consumer price 26 
index for all goods and services
16
. The cycle length of the model was three months, as most of the data 27 
sources, for the sake of efficacy, are calculated using this frequency. The model followed patients until 28 
death or the five year time horizon, whichever occurred first.  29 
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 1 
Microsimulation  2 
 3 
Microsimulation is a discrete simulation technique that facilitates modeling of the behavior of single 4 
individuals in a complex system, i.e. multiple organ dysfunction syndrome
17-19
. Microsimulation models 5 
are mathematical computer-based models that operate from the level of the individual upwards. They 6 
simulate the behaviour of the population, taking into account the heterogeneous composition of the target 7 
population without focusing on a representative or average individual. This implies that the population is 8 
stratified across health states and attributes (e.g. age, disease severity, risk exposure) identified as relevant 9 
to the problem analysed.  A hypothetical stable sample of patients with clinical characteristics based on 10 
published reports and adjusted by clinical opinion is used to generate representative patients randomly
19
.  11 
 12 
In our cost-effectiveness microsimulation analysis, up to 1,000 hypothetical patients were randomly 13 
generated, one by one, taking into account the probability that every organ in the body was affected and 14 
the degree of severity (Table 1). Patients were entered in the model one at a time with the same or 15 
different characteristics. Each organ involvement was scored from 0 to 3 (from none to severe organ 16 
involvement) and  cGvHD was classified as (i) mild cGvHD: one or two organs involved (except lungs) 17 
with no clinically-significant impairment, i.e. maximum score 1 in all affected organs; (ii) moderate 18 
cGvHD: three or more organs involved without functional impairment (maximum score 1) or at least one 19 
organ with clinically significant involvement but no major disability (maximum score 2) or lung 20 
involvement with score 1; and (iii) severe cGvHD: major disability in any organ (score of 3) or lung score 21 
2
2
. The efficacy of each treatment and organ evaluated and survival for each disease state was applied 22 
(Table 2). Transition probabilities were dependent on the individual characteristics (organ, degree of 23 
severity per organ and previous NIH global score). Patient characteristics were considered independently 24 
(eg. selection of the affected organ and degree of severity), as this potential relationship is not available in 25 
the literature. Patients generated in the same way were evaluated for each alternative treatment. 26 
 27 
Parameters of the model 28 
 29 
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Model probabilities concerning the efficacy of ECP, Rmb and Imt and the degree of severity per organ 1 
affected were obtained from published reports and internet searches of relevant medical databases (e.g. 2 
PUBMED, CINAHL, DARE, NHS EED, HTA) as well as a targeted search of relevant bone marrow 3 
transplantation-related journals 
6, 20-52
. (Table 1 and 2). Key words searched for included extracorporeal 4 
photopheresis, ECP, cGvHD treatment, cGvHD, rituximab and imatinib. The systematic review was 5 
limited to evaluations involving adults published in Spanish or English. Studies of treatment efficacy per 6 
affected organ for any time horizon were included (clinical trial, observational studies, cohort studies, 7 
cases studies). The summary measure from a meta-analysis was used to derive the probability of 8 
treatment success in our cost-effectiveness analysis. To detect which organs would be globally affected in 9 
our hypothetical patients, we searched for information on the organs affected in the studies reviewed and 10 
made a pooled analysis. Based on the clinical opinion and experience of two authors (JP and JS), the 11 
probabilities of continuing with treatment were dependent on the health status reached in each cycle 12 
(complete response 100%, partial response 65%, stable disease 33% and progression 0%). Clinical 13 
opinion was compiled using a structured questionnaire in two interviews, the first exploratory and the 14 
second for validation and consensus. Clinical authors were selected according to clinical experience and 15 
national and international research achievements. Table 3 shows the utilities associated with different 16 
disease states, the disutility associated with neutropenia and survival rates. Neutropenia is an adverse 17 
event associated with drug treatments included in our study 
53, 54
. 18 
 19 
Treatment pathways and adverse events were derived from the clinical opinion of two authors (JP and 20 
JS). Local data on healthcare resource use and costs were used and validated by the same authors
55,56
 21 
Table 4 shows the cost derived from the pre-administration of treatments, pharmacological costs based on 22 
the type of response, the cost associated with different disease states and adverse events. To determine the 23 
cost of the whole ECP treatment, the following factors were taken into account:  Therakos’ European list 24 
price for the ECP Kit (990€), the need for 20 minutes of light assembly, 5 ml of methoxsalen (Uvadex1), 25 
10,000 IU of enoxaparin, 0.5 L of physiological saline, a hematology consultation visit and 2 hours of 26 
nursing time. The initial guideline for ECP sessions, recommended by study clinicians, was 3 sessions per 27 
week during the first 2 weeks and a single session every 15 days until patient evaluation at  3 months. 28 
 29 
                                                 
1
 Uvadex is a registered trade name of Johnson And Johnson Medical Limited, New Brunswick, US. 
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In contrast to other treatments, including various monoclonal antibodies,  independent reports including 1 
Wolff et al.
8
, Flowers et al.
37
, Jagasia et al.
38 
and Miller et al.
29  
have shown that ECP does not result in an 2 
increased risk of infection. The incidence of complications or reported side-effects is < 0.003% after more 3 
than 500,000 ECP treatments worldwide since 1987 in patients with cutaneous T-cell lymphoma and 4 
graft-versus-host disease
21
. All studies essentially reported only mild side-effects, including nausea, high 5 
temperature and headache, without any associated cost. Our study made a conservative assumption which 6 
excluded the cost of infection, even though a major disadvantage of Rmb and Imt is the strong 7 
immunosuppressive effect, which may lead to life-threatening fungal infections, bacterial sepsis and viral 8 
reactivations
9
. Another factor that was not taken into consideration was the steroid sparing effect reported 9 
after ECP treatment: Couriel et al. reported a 22% cumulative discontinuation of steroids and a 10% 10 
discontinuation rate of all immunosuppressive therapy at one year after ECP initiation
57
. 11 
 12 
Probabilistic sensitivity analysis  13 
 14 
To evaluate the influence of uncertainty due to patient characteristics, parameter values and modeling 15 
assumptions on the results of the model, and to confirm the robustness of the outcomes obtained, a 16 
probabilistic sensitivity analysis was performed by simulating 1,000 times (each parameter being 17 
randomly selected from the distribution) and with 1,000 trials per analysis 
58
. For the sensitivity analysis, 18 
fixed probability distributions were selected for each variable (log-normal distribution for costs, resources 19 
used and utilities, a normal distribution for patient’s weight and height and a Dirichlet distribution for 20 
probabilities) and the parameters of each distribution were estimated according to the primary data 21 
collected
59
.  22 
 23 
Based on probabilistic sensitivity analysis, the incremental cost and incremental effect of ECP vs. 24 
comparators was represented visually using the incremental cost-effectiveness plane
60
. The horizontal 25 
axis divides the plane according to incremental cost (positive above, negative below) and the vertical axis 26 
divides the plane according to incremental effect (positive to the right, negative to the left). This divides 27 
the incremental cost-effectiveness plane into four quadrants through the origin. We included the 28 
unofficial, but broadly accepted, Spanish threshold line (30,000€/QALYs) in the plane, in order to decide 29 
whether ECP offered good value for money
61
. This threshold represents the maximum amount the 30 
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decision maker is willing to pay for health effects (maximum acceptable ceiling ratio). The intervention is 1 
deemed cost-effective if the ICER falls below this threshold and not cost-effective otherwise.  2 
An acceptability curve was then constructed from the incremental cost and QALYs between different 3 
strategies for the 1,000 simulations. The cost-effectiveness acceptability curve showed the probability that 4 
ECP was cost-effective against comparators over a range of values for the maximum acceptable ceiling 5 
ratio. 6 
 7 
Results 8 
 9 
The main organs affected in patients with cGvHD were the skin (88%), mucous membrane (43%), liver 10 
(37%), lungs (22%) and gastrointestinal tract (14%). Severity was mainly mild (range 60.7% - 93.5%) in 11 
all cases except in the lung where severity was moderate in 60% of cases. 12 
 13 
With respect to the published information obtained on the three treatments compared, the number of 14 
patients included in studies reporting data on ECP was higher than in those related to Rmb or Imt. Data 15 
related to complete response and improvement rates (complete or partial response) were higher with ECP 16 
for all affected organs except for skin, where improvement was similar to Rmb. The progression rate was 17 
higher with Imt for the skin and mucous membrane, higher with Rmb for the liver and higher with ECP 18 
for the lungs and gastrointestinal tract. However, the number of patients studied with lung and 19 
gastrointestinal involvement was lower for Rmb and Imt than for ECP. 20 
 21 
The higher purchasing cost of ECP vs. Imt was compensated for at 9 months due to its greater efficacy. 22 
Our results show the global treatment cost of ECP was € 518-4,000 higher than Rmb. The difference in 23 
disease improvement (% of complete or partial response) shows that ECP produced an improvement of 24 
6.2% after the first year vs. Rmb and 6.7% vs. Imt (Table 5). The results show that the greater efficacy of 25 
ECP lead to a gain of 0.011 QALY vs. Rmb and 0.024 QALY vs. Imt at one year and a gain of 0.062 26 
QALY vs. Rmb and 0.094 QALY vs. Imt at year five (Table 5). After 9 months, ECP was dominant 27 
(cheaper and more effective) vs. Imt for all parameters: the cost per improvement gained, the cost per LY 28 
gained and the cost per QALY gained (Table 5). After 2.5 years ECP was cost-effective vs. Rmb with an 29 
ICER below € 30,000 (29,646€ per LY gained and 24,442 € per QALY gained). 30 
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 1 
The results of the probabilistic analysis (1,000,000 different simulated patients) showed that, taking into 2 
account the uncertainty in the variables of the model, starting treatment of cGvHD with ECP remained 3 
dominant and more cost-effective versus the other alternatives (30.7% dominant vs. Rmb and 83.0% 4 
dominant vs. Imt at year 3 and 32.1% dominant vs. Rmb and 78.2% dominant vs. Imt at year 5) (Figures 2 5 
and 3). Assuming a willingness-to-pay threshold of €30.000 per QALY gained, there was a 56.5% chance 6 
at year 3 and a 70.1% chance at year 5 that ECP was a cost-effective intervention vs. Rmb and Imt. Imt 7 
was the least cost-effective treatment. This indicates that, even when the decision maker’s willingness to 8 
pay for the increment in quality-adjusted life months is almost 30,000 €, the treatment of choice should 9 
still be ECP. 10 
 11 
Discussion 12 
 13 
Economic evaluations are acquiring greater importance due to limitations on economic resources, the 14 
expense of many new treatments and the need to allocate health spending as effectively as possible and to 15 
inform decision making. Furthermore, variations in clinical practice can cause substantial differences in 16 
expenditures. For example, the number of sessions of ECP is not standardized yet in all countries. 17 
Likewise the escalation of therapy is not yet clear, which is important given that this is a salvage therapy.  18 
Traditionally, healthcare companies were required to provide evidence to demonstrate product safety, 19 
efficacy and quality for the purpose of registration and reimbursement 
14, 15
. Increasingly, a value for 20 
money demonstration, which requires companies to make economic evaluations to support the 21 
reimbursement process, has been added, increasing the importance of health economic evaluations. New 22 
national and international guidelines are being published and updated continuously, representing an 23 
increase in healthcare sources to aid decision making and in the number of countries with value for 24 
money demonstrations
15, 61
.  25 
 26 
There are no reported economic evaluations including ECP, Rmb or Imt as third-line treatment of 27 
cGvHD. However, a recent consensus conference on clinical practice in cGvHD involving German-28 
speaking countries included ECP as a second-line treatment due to its safety profile and well documented 29 
activity 
8
. Evaluation of our conclusions should consider not only that the Spanish health system is 30 
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universal and public, but also that the elements that most influenced the results of the CEA were the 1 
number of sessions of ECP, the dosing guidelines of rituximab and imatinib and the cost of day hospital.  2 
 3 
There are some economic evaluations of GvHD. A recent Spanish study evaluated the cost-effectiveness 4 
of posaconazole vs. fluconazole in preventing invasive fungal infections in allogeneic hematopoietic stem 5 
cell transplantation patients with graft-versus-host disease
62
, using a Markov model. Our study used 6 
microsimulation because it allowed us to start from the clinical behaviour of the patient and can 7 
incorporate different responses at different organ levels. Therefore, the model differs from aggregate 8 
models (Markov models), in which the explanatory variables represent group properties
17-19
. Although 9 
Markov models are widely used in economic evaluation, as they facilitate the representation of recurrent 10 
events, they assume that patients who reach a health status are homogenous. This is usually overcome by 11 
creating more health states in order to ensure that this is so. In our specific case, the proliferation of health 12 
states, and of possible responses (complete response, partial response, stable disease and progression) for 13 
each organ (skin, liver, lungs,..) does not solve the problem because, in order to evaluate the result of 14 
treatment, a combined score which indicates disease severity (mild, moderate, severe) must be calculated. 15 
This require around 1024 (4
5
) different health states grouped according to severity, meaning that the use 16 
of a Markov model would be unviable. In contrast, microsimulation, which evaluates the individual 17 
dynamically, is capable of following the complete natural history of that individual. However, on 18 
drawback of microsimulation is that it requires the generation of a large number of individuals in order to 19 
adjust to the pre-established parameters and minimize the error of the simulation. This requires many 20 
hours, or even days, of computing time.   21 
 22 
Our study has some limitations. Firstly, we used a theoretical mathematical model which made different 23 
assumptions and used data from different sources. However, economic evaluation models are tools that 24 
help decision making, and make it easier to represent real world complexity in a simplified and 25 
understandable way. Thus, models help to simulate alternative scenarios if there is no evidence available 26 
to estimate some probabilities or there is a lack of published studies investigating long term outcomes of 27 
patients receiving these treatments or costs. In fact, microsimulation models have some major advantages 28 
over cohort-based models, increasing the reliability of the results and being largely compatible with the 29 
existing state of the art, evidence-based literature. Secondly, the protocols of treatment and the time 30 
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horizon of studies were variable, ranging from a cycle of treatment every 1 and 4 weeks and a time 1 
horizon of 3 and 6 months, but in most cases the treatment is tailored to the clinical response. Thirdly, our 2 
analysis excluded the reduction in immunosuppressive therapies attributable to ECP, even though some 3 
studies have provided evidence of such as reduction due to the fact that ECP treatment is associated with 4 
lower morbidity and mortality
63, 64
. 5 
 6 
Cost-effectiveness evaluations of healthcare interventions depend on strong clinical evidence in order to 7 
establish benefits and risks.  Estimates derived from large-scale, multicenter, randomized clinical trials 8 
are widely considered as the ‘gold standard’ for assessing efficacy,  Therefore, our results should be taken 9 
with caution, as they depend on data from small studies or case studies, which are inherently more 10 
uncertain and have a lower level of evidence. However, no other data is available.   11 
  12 
Conclusion 13 
The efficacy and safety profile of ECP has been widely proven. Although only 5-10% of circulating 14 
mononuclear cells are treated during one ECP procedure, the treatment has long-lasting 15 
immunomodulatory effects
65
. The main advantage of ECP treatment is the lower frequency of treatment-16 
related side effects, and the only disadvantages are the practical efforts required (availability of trained 17 
staff) and higher acquisition costs to implement the therapy in a specific center
65
. However, our 18 
microsimulation study results provide evidence that ECP is cheaper and more effective than imatinib and 19 
more cost-effective than rituximab, when using currently-accepted Spanish willingness-to-pay thresholds. 20 
21 
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Fig. 2 Incremental cost-effectiveness plane (1, 3 and 5 years) 
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Fig. 3 Acceptability curve (5 years) 
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Table 1. Organ involvement 
  
Proportion  
of organ affected 
Severity per organ 
Skin 
88% 
(95%CI
a
: 86-90) 
Mild 73.1% (95%CI: 61-85) 
Moderate 17.3% (95%CI: 7-28) 
Severe 9.6% (95%CI: 2-18) 
Mucous  
membrane 
43% 
(95%CI
 a
: 40-48) 
Mild 93.5% (95%CI: 87-100) 
Moderate 6.5% (95%CI: 0-13) 
Severe 0.0%  (-) 
Lung 
22% 
(95%CI
 a
: 17-26) 
Mild 33.3% (95%CI: 9-57) 
Moderate 60.0% (95%CI: 35-85) 
Severe 6.7% (95%CI: 0-19) 
Liver  
38% 
(95%CI
 a
: 34-42) 
Mild 70.2% (95%CI: 57.83) 
Moderate 14.9% (95%CI: 5-25) 
Severe 14.9% (95%CI: 5-25) 
GI 
14% 
(95%CI
 a
: 10-19) 
Mild 60.7% (95%CI: 43-79) 
Moderate 32.1% (95%CI: 15-49) 
Severe 7.1% (95%CI:0-17) 
 
a.95%CI: 95% Confidence Interval. GI: Gastrointestinal tract. 
Sources: Pérez-Simón et al., 2008; Lee and Flowers, 2008; Scarisbrick et al., 2008; Bolwell et al. 1990; Bloom et 
al. 1991; Owsianowski et al. 1994; Sniecinski et al. 1995; Balda et al. 1996; Crovetti et al. 1996; Abhvankar et al. 
1998; Miller et al. 1998; Sniecinski et al. 1998; Zic et al.1999; Biagi et al. 2000; Alcindor et al. 2001; Gorgun et al. 
2002; Perseghin et al. 2002; Biagi et al. 2007; Flowers et al. 2008; Jagasia et al. 2009; Pérez-Carmona et al. 2009; 
Ratanatharathorn et al. 2003; Canninga-van et al. 2004; Okamoto et al. 2006; Cutler et al. 2006; Zaja F, 2007; von 
Bonin et al. 2008; Mohty et al. 2008; Teshima et al. 2009; Peterson et al. 2009; Magro et al. 2008; Stadler et al. 2009; 
Magro et al. 2009; Olivieri et al. 2009. 
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Table 2. Efficacy (Mean and 95% Confidence Interval) of ECP, Rtm and Imt. 
Literature review results. Model probabilities per cycle (3 months)  
  Skin Muc. memb Lung Liver GI 
ECP (n: 723) (n: 256) (n: 128) (n: 261) (n: 70) 
Complete Response 
42% 
(38-45) 
47% 
(41-53) 
25% 
(17-33) 
42% 
(36-48) 
23% 
(13-33) 
Partial Response 
27% 
(23-30) 
9% 
(5-12) 
14% 
(8-20) 
16% 
(12-21) 
9% 
(2-15) 
Stable disease 
9% 
(7-11) 
1% 
(0-2) 
1% 
(0-2) 
0% 
(-) 
0% 
(-) 
Progression 
23% 
(20-26) 
43% 
(37-49) 
60% 
(52-69) 
42% 
(36-48) 
69% 
(58-79) 
Rmb (n: 167) (n: 44) (n: 10) (n: 30) (n: 0)* 
Complete Response 
41% 
(33-48) 
18% 
(7-30) 
0% 
(-) 
3% 
(0-10) 
0% 
(-) 
Partial Response 
35% 
(28-43) 
30% 
(16-43) 
30% 
(2-58) 
27% 
(11-42) 
0% 
(-) 
Stable disease 
4% 
(1-7) 
9% 
(1-18) 
20% 
(0-45) 
10% 
(0-21) 
0% 
(-) 
Progression 
20% 
(14-26) 
43% 
(29-58) 
50% 
(19-81) 
60% 
(42-78) 
0% 
(-) 
Imt (n: 58) (n: 20) (n: 31) (n: 1) (n: 10) 
Complete Response 
17% 
(8-27) 
5% 
(0-15) 
13% 
(1-25) 
0% 
(-) 
20% 
(0-45) 
Partial Response 
43% 
(30-56) 
25% 
(6-44) 
39% 
(22-56) 
0% 
(-) 
40% 
(10-70) 
Stable disease 
7% 
(0-13) 
0% 
(-) 
10% 
(0-20) 
0% 
(-) 
30% 
(2-58) 
Progression 
33% 
(21-45) 
70% 
(50-90) 
39% 
(22-56) 
100% 
(-) 
10% 
(0-29) 
*100% stable disease assumed in the model. ECP: Extra-corporeal photopheresis. 
Rmb: Rituximab. Imt: Imatinib. Muc.memb: Mucous membrane. GI: 
Gastrointestinal tract.  
 
Sources: ECP: Scarisbrick et al., 2008; Bolwell et al. 1990; Bloom et al. 1991; Owsianowski et al. 1994; Sniecinski 
et al. 1995; Balda et al. 1996; Crovetti et al. 1996; Abhvankar et al. 1998; Miller et al. 1998; Sniecinski et al. 1998; 
Table
2 
 
Zic et al.1999; Biagi et al. 2000; Alcindor et al. 2001; Gorgun et al. 2002; Perseghin et al. 2002; Biagi et al. 2007; 
Flowers et al. 2008; Jagasia et al. 2009; Pérez-Carmona et al. 2009. Rmb: Ratanatharathorn et al. 2003; Canninga-van 
et al. 2004; Okamoto et al. 2006; Cutler et al. 2006; Zaja F, 2007; von Bonin et al. 2008; Mohty et al. 2008; Teshima 
et al. 2009; Peterson et al. 2009. Imb: Magro et al. 2008; Stadler et al. 2009; Magro et al. 2009; Olivieri et al. 2009. 
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Table 3. Model utilities, disutility and survival. 
 
 Value Source 
Utilities   
Complete response 0.836 Lee et al., 1998 
Partial response 0.786 Pidala et al., 2009 
Stable disease 0.736 Pidala et al., 2009 
Progression 0.696 Pidala et al., 2009 
Disutility   
Neutropenia 0.09 Nafees et al., 2008 
Neutropenia (days per episode) 6 Expert Opinion 
Survival   
Low risk 92% Pérez-Simón, 2009 
Medium risk 71% Pérez-Simón, 2009 
High risk 9% Pérez-Simón, 2009 
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Table 4. Pre-administration costs, pharmacological and administration costs, cost 
per disease state and cost of adverse events.  
 ECP Rituximab Imatinib 
Pre-administration costs  140.03 140.03 140.03 
Pharmacological and administration costs    
Cost per session   1,125.50* 1,996.43 58.83 
Standard care (3 months)  1,177.38 
First 3 months  12,380.49  7,985.73 5,294.50 
Complete response    
From 4 months to 6 months  3,376.50  - 5,294.50 
From 7 months to 9 months  3,376.50  - - 
From 10 months to end of treatment  - - - 
Partial response    
From 4 months to 6 months  4,502.00  7,985.73 5,294.50 
From 7 months to 9 months  3,376.50 - 5,294.50 
From 10 months to end of treatment  3,376.50 - 5,294.50 
Stable disease    
From 4 months to 6 months  6,752.99 7,985.73 5,294.50 
From 7 months to 9 months  4,502.00 7,985.73 5,294.50 
From 10 months to end of treatment  3,376.50  - 5,294.50 
Cost per disease state    
Complete response (cost per visit)  59.87 119.74 59.87 
First 3 months  299.35 598.70 299.35 
From 4 months to 6 months  119.74 239.48 119.74 
From 7 months to 9 months  59.87 119.74 59.87 
From 10 months to end of treatment  59.87 119.74 59.87 
Partial response (cost per visit)  1,735.92 
First 3 months  10,415.52 
From 4 months to 6 months  5,207.76 
From 7 months to 9 months  3,471.84 
From 10 months to end of treatment  1,735.92 
Stable disease (cost per visit)  2,674.96 
First 3 months  16,049.73 
From 4 months to 6 months  8,024.87 
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From 7 months to 9 months  5,349.91 
From 10 months to end of treatment  2,674.96 
Progression  5,290.04 
First 3 months  42,320.32 
From 4 months to 6 months  21,160.16 
From 7 months to 9 months  21,160.16 
From 10 months to end of treatment  21,160.16 
Adverse events (AEs)    
Neutropenia    
Cost  689,18 
Frequency (%) 0 20 16 
Hypogammaglobulinemia    
Cost  475,66  
Frequency (%) 0 20 0 
AEs related to infusion    
Cost  8,58  
Frequency (%) 0 27 0 
Catheter-related    
Cost  15,18  
Frequency (%) 10 0 0 
Total cost AEs (annual)  1.52 235.32 108.09 
 
Sources: eSalud, 2010; General Spanish Council of Pharmacists, 2010; expert opinion;  
Includes ECP kit, light assembly, Uvadex
TM
 (methoxsalen), enoxaparin, physiological 
saline, hematology visits and nursing hours. Source: Johnson & Johnson internal data 
and panel of experts. All costs are expressed in 2010 euros. ECP: Extra-corporeal 
photophoresis. 
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Table 5. Cost per improvement gained, cost per life year gained and cost per 1 
quality-adjusted life year gained at 1, 3 and 5 years (ECP versus alternatives) 2 
 3 
 COST 
Cumulative 
(€) 
COST 
Difference 
Impa Impa 
gained 
Cost per 
impa 
LYb LY
 b 
gained 
ICER
 c QALY
 
d
 
QALY
 
d 
gained 
ICUR
 e 
1 year            
ECP  66,880.80 €   76.2%   0.933   0.740   
Rmb  64,554.14 €   2,326.66 €  69.9% 6.2%  37,412.75 €  0.928 0.005  501,868.32 €  0.728 0.011 202,646.35€  
Imt  67,966.49 €  - 1,085.68 €  69.4% 6.7%  Dominant  0.919 0.014  Dominant  0.715 0.024  Dominant  
3 years            
ECP  78,140.95 €   83.0%   2.581   2.111   
Rmb  77,465.83 €   675.12 €  81.0% 2.0%  34,031.64 €  2.547 0.034  20,053.89 €  2.073 0.038  17,745.12 €  
Imt  80,012.36 €  - 1,871.41 €  80.8% 2.2%  Dominant  2.523 0.058  Dominant  2.049 0.062  Dominant  
5 years            
ECP  85,700.66 €   79.2%   4.044   3.335   
Rmb  85,182.83 €   517.83 €  77.5% 1.7%  31,260.52 €  3.981 0.063  8,178.73 €  3.273 0.062  8,330.16 €  
Imt  87,438.76 €  -1,738.10 €  77.0% 2.1%  Dominant  3.947 0.097  Dominant  3.240 0.094  Dominant  
 4 
a. Imp: Improvement (% of complete or partial response). b. LY: Life year. c. ICER: 5 
Incremental cost-effectiveness ratio. d. QALY: Quality adjusted life year.  6 
e. ICUR: Incremental cost-utility ratio. ECP: Extra-corporeal photophoresis. Rmb: 7 
Rituximab. Imt: Imatinib.  8 
Table
